Forest Laboratories (FRA:FQX) Change In Receivables : €18 Mil (TTM As of Mar. 2014)

View and export this data going back to . Start your Free Trial

What is Forest Laboratories Change In Receivables?

Forest Laboratories's change in receivables for the quarter that ended in Mar. 2014 was €-61 Mil. It means Forest Laboratories's Accounts Receivable increased by €61 Mil from Dec. 2013 to Mar. 2014 .

Forest Laboratories's change in receivables for the fiscal year that ended in Mar. 2014 was €17 Mil. It means Forest Laboratories's Accounts Receivable declined by €17 Mil from Mar. 2013 to Mar. 2014 .

Forest Laboratories's Accounts Receivable for the quarter that ended in Mar. 2014 was €417 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Forest Laboratories's Days Sales Outstanding for the three months ended in Mar. 2014 was 48.19.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Forest Laboratories's liquidation value for the three months ended in Mar. 2014 was €-2,140 Mil.

Forest Laboratories Change In Receivables Historical Data

The historical data trend for Forest Laboratories's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Forest Laboratories Change In Receivables Chart

Forest Laboratories Annual Data

Trend

Mar05

Mar06

Mar07

Mar08

Mar09

Mar10

Mar11

Mar12

Mar13

Mar14

Change In Receivables

Get a 7-Day Free Trial

-19.32

-42.66

48.22

-4.82

16.81

Forest Laboratories Quarterly Data
	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14
Change In Receivables	Get a 7-Day Free Trial															-61.86	-12.11	46.87	44.87	-61.38

Forest Laboratories Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €18 Mil.

Forest Laboratories (FRA:FQX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Forest Laboratories's Days Sales Outstanding for the quarter that ended in Mar. 2014 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	417.065	/	789.717	*	91
=	48.19

2. In Ben Graham's calculation of liquidation value, Forest Laboratories's accounts receivable are only considered to be worth 75% of book value:

Forest Laboratories's liquidation value for the quarter that ended in Mar. 2014 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	1556.655	-	4230.972	+	0.75 * 417.065	+	0.5 * 442.956
=	-2,140

Forest Laboratories Change In Receivables Related Terms

Thank you for viewing the detailed overview of Forest Laboratories's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Forest Laboratories (FRA:FQX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Forest Laboratories Inc (FRA:FQX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.frx.com

Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.

Forest Laboratories (FRA:FQX) Headlines

No Headlines